Amer Zeidan, MBBS, MHS is a Professor of Medicine at Yale School of Medicine, and an internationally recognized expert in myeloid malignancies especially acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He is the Chief of the Division of Hematologic Malignancies, Director of Hematology Early Therapeutics Research, and the Assistant Director of the Clinical Trial Office for Hematology at Yale Comprehensive Cancer Center. Dr. Zeidan obtained his medical degree with honors from University of Jordan and completed a Hematology/Oncology fellowship at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr Zeidan conducts research on the development of novel therapies for MDS and AML with a focus on targeted and immunotherapy-based approaches.
Dr. Zeidan serves as study chair and principal investigator of multiple global, registrational, randomized, cooperative group and industry sponsored as well as investigator-initiated clinical trials. He contributed to multiple drug approvals including oral decitabine/cedazuridine in AML (NEJM, co-first author) and MDS (Lancet Haematology), imetelstat in MDS (Lancet, senior author), luspatercept for MDS in second line (NEJM) and first line (Lancet) indications. Dr Zeidan founded and chairs the International Consortium for MDS (icMDS) where he led important scientific initiatives including revising the IWG response criteria for higher risk MDS (Blood Journal), standardizing eligibility criteria (Blood journal) and reporting for MDS clinical trials (Blood Journal).
Dr. Zeidan’s work has been recognized by several prestigious awards including an Honorary Master of Arts from Yale University, 2026 King Hussein Cancer Research Lifetime Achievement Award (International track), 2026 H.J. Khoury Excellence in Research Award of the International Academy of Clinical Hematology, Leukemia and Lymphoma Society Scholar in Clinical Research award, National Cancer Institute Cancer Clinical Investigator Team Leadership award, AAMDSIF/Evan’s Foundation-MDS Clinical Research Consortium Fellowship award, Tito Bastianello Young Investigator Award, and the ASCO Young Investigator Award. Dr. Zeidan authored more than 450 peer-reviewed publications and book chapters.